B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 8.767 NOK -5.16% Market Closed
Market Cap: 342.7m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Investor Relations

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. Martin Olin
Chief Executive Officer
No Bio Available
Mr. Rune Skeie
Chief Financial Officer
No Bio Available
Ms. Cristina Oliva M.D.
Chief Medical Officer
No Bio Available
Graham Morell
Head of IR
No Bio Available
Ms. Gayle M. Mills M.B.A
Chief Business Officer
No Bio Available
Dr. Akil Jackson
Medical Director
No Bio Available

Contacts

Address
HORDALAND
Bergen
Jonas Lies vei 91
Contacts
+4755961159.0
www.bergenbio.com